

PARMAX PHARMA LIMITED

Financial statement for the quarter ended 30.06.2013

1	Net Sale / Income from Operation			
	Commission received	-		
	Other income	-		
	(A)		-	
2	Other Income	-	-	
3	Total Expenditure			
	(a) Increase / Decrease in stock		-	
	(b) Purchase of Shares & Securities		-	
			-	
	(c) Staff Cost			
	Salary & Directors Remuneration	-		
	Staff Welfare	-	-	
	(d) Other Expenditure		35,204.00	
4	(B)		35,204.00	
	Profit (+ or -) before Dep.(A-B)			(35,204.00)
	Depreciation			-
	Profit (+ or -) after Dep.			(35,204.00)

Unaudited Financial Results (Provisional) for the Quarter Ended 30.06.2013


Sr. No	Particulars	3 months ended 30.06.2013	Corresponding 3 months ended 30.06.2012	Six month ended 30.06.2013	Corresponding Six month ended 30.06.2012	Year Ended 31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	a Net Sales/Income from Operations	-	-	-	-	-
	b Other operating Income	-	-	-	-	-
	Total Income	-	-	-	-	-
2	Expenditure					
	a :(Increase)/Decrease in Stock-in-Trade	-	-	-	-	-
	b : Consumption of Raw Material	-	-	-	-	-
	c : Purchase of traded goods	-	-	-	-	-
	d : Employees Cost	-	-	-	-	-
	e : Depreciation	-	-	-	-	-
	f : Other Expenditure	35,204.00	12,500.00	35,204.00	25,000.00	50,000.00
	g Total	35,204.00	12,500.00	35,204.00	25,000.00	50,000.00
3	Profit from Operations before other Income, Interest and Exceptional Items (1-2)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
4	Other Income	-	-	-	-	-
5	Profit before Interest and Exceptional Items (3+4)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
6	Interest	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7+8)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
10	Tax Expenses	-	-	-	-	-
11	Net Profit from Ordinary Activities after Tax (9-10)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
12	Extraordinary item	-	-	-	-	-
13	Net Profit for the period (11-12)	(35,204.00)	(12,500.00)	(35,204.00)	(25,000.00)	(50,000.00)
14	Paid-up Equity Share Capital-[Face Value. Rs 10]	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00
15	Reserve excluding revaluation reserve	-	-	-	-	578,089.00
16	Basic & Diluted EPS	-	-	-	-	-
17	Public Shareholding					
	Number of Shares					
	% of Shareholding					
18	Promoters and promoter group Shareholding					
	a Pledge / Encumbered					
	Number of Shares	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total Share Capital of the Company)	NIL	NIL	NIL	NIL	NIL
	b Non encumbered					
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of Shares (as a % of the total Share Capital of the Company)					

Notes :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on
- There were no investors complaints during the quarter ended 30th June 2013
- Previous years figures has been regroup / rearranged wherever necessary.

PARMAX PHARMA LIMITED

Alkesh M Gopani
Director



Place Hadamtala (Rajkot)

Date:

Date :

Auditor's Limited Review Report

On Unaudited Financial Results

To
The Board of Directors,
Parmax Pharma Limited

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **30th June 2013**. This statement is the responsibility of the Company's Management.


A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regard to the figures of quarter ended 30th June 2013.

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figures as per the accounts (which are however within the allowed limit of 10% or Rs. 10 lacs, whichever is higher).

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

Place: Ahmedabad
Date: 14/07/2013



FOR ARVIND A. THAKKAR & CO.
CHARTERED ACCOUNTANTS

(Signature)
A. A. THAKKAR
(SOLE PROPRIETOR)

Membership No. 014334